全文获取类型
收费全文 | 26988篇 |
免费 | 1317篇 |
国内免费 | 179篇 |
专业分类
耳鼻咽喉 | 206篇 |
儿科学 | 573篇 |
妇产科学 | 471篇 |
基础医学 | 2962篇 |
口腔科学 | 650篇 |
临床医学 | 2156篇 |
内科学 | 7054篇 |
皮肤病学 | 503篇 |
神经病学 | 3158篇 |
特种医学 | 865篇 |
外科学 | 3994篇 |
综合类 | 44篇 |
一般理论 | 5篇 |
预防医学 | 1118篇 |
眼科学 | 456篇 |
药学 | 1542篇 |
中国医学 | 30篇 |
肿瘤学 | 2697篇 |
出版年
2024年 | 26篇 |
2023年 | 180篇 |
2022年 | 398篇 |
2021年 | 774篇 |
2020年 | 460篇 |
2019年 | 642篇 |
2018年 | 722篇 |
2017年 | 564篇 |
2016年 | 645篇 |
2015年 | 718篇 |
2014年 | 1036篇 |
2013年 | 1316篇 |
2012年 | 2055篇 |
2011年 | 2059篇 |
2010年 | 1195篇 |
2009年 | 1098篇 |
2008年 | 1808篇 |
2007年 | 1875篇 |
2006年 | 1721篇 |
2005年 | 1698篇 |
2004年 | 1667篇 |
2003年 | 1406篇 |
2002年 | 1365篇 |
2001年 | 235篇 |
2000年 | 153篇 |
1999年 | 189篇 |
1998年 | 260篇 |
1997年 | 216篇 |
1996年 | 199篇 |
1995年 | 175篇 |
1994年 | 137篇 |
1993年 | 136篇 |
1992年 | 143篇 |
1991年 | 115篇 |
1990年 | 112篇 |
1989年 | 82篇 |
1988年 | 88篇 |
1987年 | 90篇 |
1986年 | 69篇 |
1985年 | 65篇 |
1984年 | 91篇 |
1983年 | 50篇 |
1982年 | 49篇 |
1981年 | 50篇 |
1980年 | 38篇 |
1979年 | 32篇 |
1978年 | 24篇 |
1977年 | 32篇 |
1974年 | 22篇 |
1968年 | 23篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
Vladan Milosevic Joanna Kopecka Iris C. Salaroglio Roberta Libener Francesca Napoli Stefania Izzo Sara Orecchia Preeta Ananthanarayanan Paolo Bironzo Federica Grosso Fabrizio Tabbò Valentina Comunanza Teodora Alexa-Stratulat Federico Bussolino Luisella Righi Silvia Novello Giorgio V. Scagliotti Chiara Riganti 《International journal of cancer. Journal international du cancer》2020,146(1):192-207
993.
Ester Orlandi MD Stefano Cavalieri MD Roberta Granata MD Piero Nicolai MD Paolo Castelnuovo MD Cesare Piazza MD Alberto Schreiber MD Mario Turri-Zanoni MD Pasquale Quattrone MD Rosalba Miceli MD Gabriele Infante PhD Fausto Sessa MD Carla Facco MD Giuseppina Calareso MD Nicola Alessandro Iacovelli MD Davide Mattavelli MD Alberto Paderno MD Carlo Resteghini MD Laura Deborah Locati MD Lisa Licitra MD Paolo Bossi MD 《The Laryngoscope》2020,130(4):857-865
994.
995.
Pini Prato Alessio Arnoldi Rossella Dusio Maria Pia Cimorelli Angela Barbetta Vincenza Felici Enrico Barbieri Paola Barbero Stefano Carlini Claudio Petralia Paolo Mattioli Girolamo Roveta Annalisa Maconi Antonio 《Pediatric surgery international》2020,36(2):209-218
Pediatric Surgery International - Since Hirschsprung’s disease (HSCR) already proved to benefit from robotic surgery, we aimed at describing a wider series of patients with this rare disease... 相似文献
996.
David J. Seiffge MD Gian Marco De Marchis MD Masatoshi Koga MD PhD Maurizio Paciaroni MD Duncan Wilson PhD Manuel Cappellari MD Kosmas Macha MD Georgios Tsivgoulis MD Gareth Ambler PhD Shoji Arihiro MD Leo H. Bonati MD Bruno Bonetti MD Bernd Kallmünzer MD Keith W. Muir MD PhD Paolo Bovi MD Henrik Gensicke MD Manabu Inoue MD Stefan Schwab MD Shadi Yaghi MD Martin M. Brown MD PhD FRCP Philippe Lyrer MD Masahito Takagi MD PhD Monica Acciarrese MD Hans Rolf Jager MD FRCP Alexandros A. Polymeris MD Kazunori Toyoda MD PhD Michele Venti MD Christopher Traenka MD Hiroshi Yamagami MD PhD Andrea Alberti MD Sohei Yoshimura MD PhD Valeria Caso MD Stefan T. Engelter MD David J. Werring MD PhD FRCP the RAF RAF-DOAC CROMIS- SAMURAI NOACISP Erlangen and Verona registry collaborators 《Annals of neurology》2020,87(5):677-687
997.
Prevalence and Clinical Aspects of Mild Cognitive Impairment in Parkinson's Disease: A Meta-Analysis
Chiara Baiano PhD Paolo Barone MD PhD Luigi Trojano MD PhD Gabriella Santangelo PhD 《Movement disorders》2020,35(1):45-54
Mild cognitive impairment associated with Parkinson's disease (PD) is a risk factor for the development of dementia. Despite the importance of early identification of mild cognitive impairment in PD, its prevalence and clinical correlates are still debated. The present meta-analysis provides a robust estimate of prevalence rate of mild cognitive impairment in PD according to the Movement Disorder Society clinical criteria and to explore the differences between PD patients with and without mild cognitive impairment in demographic, clinical, and neuropsychiatric features. A systematic literature search was performed up to April 2019 using PsycInfo (PROQUEST), PubMed, and Scopus. From 4706 titles and abstracts, 41 studies were selected (n = 7053 patients). Pooled mild cognitive impairment prevalence was 40% on a total sample of 7053 PD patients (95% confidence interval = 36–44; Q = 490.14, P < 0.0001; I2 = 91.84%) with a higher frequency for the multiple domain subtype (31%; 95% confidence interval = 23–41, Q = 93.24; P < 0.0001; I2 = 92.49%). Meta-regression analysis revealed that stage of PD moderate prevalence estimates of mild cognitive impairment (β = 2.80; P = 0.008). Mild cognitive impairment in PD was associated with older age, lower education, longer disease duration, higher levodopa equivalent daily dose, more severe motor symptoms, and postural instability/gait difficulty motor subtype, poorer quality of life, higher levels of apathy, and depression. The present meta-analysis indicated that mild cognitive impairment in PD is a frequent cognitive status deserving to be early detected by means of standardized cognitive assessments in clinical practice. © 2019 International Parkinson and Movement Disorder Society 相似文献
998.
Maria Grazia Forese Marta Pellegatta Paolo Canevazzi Giorgia S. Gullotta Paola Podini Cristina Rivellini Stefano C. Previtali Marco Bacigaluppi Angelo Quattrini Carla Taveggia 《Glia》2020,68(1):95-110
We have previously reported that prostaglandin D2 Synthase (L-PGDS) participates in peripheral nervous system (PNS) myelination during development. We now describe the role of L-PGDS in the resolution of PNS injury, similarly to other members of the prostaglandin synthase family, which are important for Wallerian degeneration (WD) and axonal regeneration. Our analyses show that L-PGDS expression is modulated after injury in both sciatic nerves and dorsal root ganglia neurons, indicating that it might play a role in the WD process. Accordingly, our data reveals that L-PGDS regulates macrophages phagocytic activity through a non-cell autonomous mechanism, allowing myelin debris clearance and favoring axonal regeneration and remyelination. In addition, L-PGDS also appear to control macrophages accumulation in injured nerves, possibly by regulating the blood–nerve barrier permeability and SOX2 expression levels in Schwann cells. Collectively, our results suggest that L-PGDS has multiple functions during nerve regeneration and remyelination. Based on the results of this study, we posit that L-PGDS acts as an anti-inflammatory agent in the late phases of WD, and cooperates in the resolution of the inflammatory response. Thus, pharmacological activation of the L-PGDS pathway might prove beneficial in resolving peripheral nerve injury. 相似文献
999.
Vegezzi Elisa Berzero Giulia Barbetta Desiree Colombo Anna Amelia Borsani Oscar Bernasconi Paolo Compagno Francesca Zecca Marco Campanini Giulia Simoncelli Anna Paoletti Matteo Pichiecchio Anna Baldanti Fausto Brunetti Enrico Marchioni Enrico 《Journal of neurovirology》2020,26(2):257-263
Journal of NeuroVirology - The aim of this study was to review the quality of the diagnostic work-up for acute encephalitis carried out at our center in a cohort of patients with hematological... 相似文献
1000.
Erika Borlenghi Chiara Cattaneo Elisa Cerqui Silvana Archetti Diego Bertoli Daniela Bellotti Doriana Gramegna Giulia Soverini Margherita Oberti Francesca Schieppati Chiara Pagani Angela Passi Margherita Sciumé Mirko Farina Cecilia Carbone Claudia Crippa Daniela Dalceggio Alessandra Tucci Giuseppe Rossi 《Hematological oncology》2020,38(5):754-762
Consolidation treatment in acute myeloid leukemia (AML) patients achieving complete remission (CR) is warranted. High-dose cytarabine (HDAC) is considered first choice in favorable risk and an option in intermediate-risk AML. However, its optimal dose and schedule, as well as the benefit of additional chemotherapy agents remain controversial. Herein, we report on the long-term outcome of consecutive unselected AML patients treated with repeated courses of HDAC, with the addition of idarubicin, followed by autologous peripheral blood stem cell (PBSC) support, in order to limit toxicity, according to Northern Italy Leukemia Group (NILG) AML-01/00 study (EUDRACT number 00400673). Among 338 patients consecutively diagnosed from 2001 to 2017 at our center, 148 with high-risk AML (adverse cytogenetic, isolated FLT3-internal tandem duplication mutation, refractory to first induction) were addressed to allogeneic stem cell transplant. All other cases, 186 patients (55%), median age 53 (range 19–75), were considered standard-risk and received the NILG AML-01/00 program. After achieving CR, patients were mobilized with cytarabine 8 g/sqm to collect autologous CD34+-PBSC and received three consolidation cycles with HDAC (20 g/sqm) plus idarubicin (20 mg/sqm) per cycle, followed by reinfusion of limited doses of CD34+ PBSC (1-2x106/kg). The program was completed by 160 (86%) patients. Toxicity was acceptable. Neutrophils recovered a median of 10 days. Treatment-related mortality was 3/160 (1.8%). After a median follow-up of 66.4 months, overall survival (OS) and relapse-free survival (RFS) at 5-years were 61.4% and 52.4%, respectively. Twenty-eight selected patients aged >65 had similar outcomes. According to European leukemia net-2010 classification, the OS and RFS at 5-years were 76.4% and 65% in favorable risk, without differences between molecular subgroups, 52.3% and 47.2% in Intermediate-I, 45.2% and 36.5% in Intermediate-II risk patients, respectively. In conclusion, consolidation including repeated courses of high dose cytarabine and idarubicin, with limited PBSC support, proved feasible and very effective in nonhigh risk patients. The incorporation of novel agents in its backbone may be tested to further improve patient's prognosis. 相似文献